

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,

Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

• Email: contact@alkem.com • Website: www.alkemlabs.com

• CIN: L00305MH1973PLC174201

19th May, 2023

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Dear Sirs,

Sub: Intimation under Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to our earlier communication dated 29th March, 2017, the Company had entered into Amended and Restated Shareholders' Agreement dated 29th March, 2017 ("**Shareholders' Agreement**").

The Board of Directors of the Company at their meeting held today i.e. 19th May, 2023 have approved the execution of amendment agreement to the Shareholders' Agreement ("**Amendment Agreement**") to include the Dhananjay and Madhurima Singh Trust ("**DMS Trust**"), which was settled by Late Mr. Dhananjay Kumar Singh for the benefit of his family members, as a member to the Shareholders' Group II and to update the list of members in Shareholders' Group I and Shareholders' Group II to reflect the changes in the constituents thereof since the date of the Shareholders Agreement. The Company also proposes to amend the Articles of Association of the Company, subject to the approval of shareholders of the Company at its ensuing Annual General Meeting to give effect to the abovementioned changes.

It is to be noted that the execution of the said Amendment Agreement will not result in any effective change in management and control of the Company.

The important terms and conditions of the Amendment Agreement are stated below:

1.	Name(s) of Parties with whom the agreement is entered	1. Alkem Laboratories Limited (" the Company ") 2. Shareholders' Group I comprising: i. Manju Singh ii. Sarandhar Singh iii. Srinivas Singh iv. Satish Kumar Singh v. Premlata Singh vi. Sarvesh Singh vii. Annapurna Singh viii. Sandeep Singh ix. Inderjit Kaur Arora x. Samprada & Nanhamati Singh Family Trust
----	---	--



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,

Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

• Email: contact@alkem.com • Website: www.alkemlabs.com

• CIN: L00305MH1973PLC174201

		3. Shareholders' Group II comprising: <ul style="list-style-type: none"> i. Basudeo N. Singh ii. Madhurima Singh iii. Divya Singh iv. Aniruddha Singh v. Mritunjay Kumar Singh vi. Seema Singh vii. Meghna Singh viii. Shrey Shree Anant Singh ix. Archana Singh x. Dhananjay and Madhurima Singh Trust
2.	Purpose of entering into the agreement	Include the name of Dhananjay and Madhurima Singh Trust ("DMS Trust") as a member to the Shareholders' Group II and to update the list of members in Shareholders' Group I and Shareholders' Group II to reflect the changes in the constituents thereof since the date of the Amended and Restated Shareholders Agreement dated 29 th March, 2017 ("Shareholders Agreement").
3.	Shareholding, if any, in the entity with whom the agreement is executed	Not Applicable
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure	The changes in the Amendment Agreement are only with respect to updating the list of members forming part of Shareholders Group I and Shareholders Group II. Hence, the parties to the Amendment Agreement shall be subject to the existing rights and obligations of the Shareholders' Agreement.
5.	Whether the said parties are related to promoter/promoter group companies in any manner. If yes, nature of relationship	The parties to the Amendment Agreement are promoters of the Company.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	Not applicable
7.	In case of issuance of shares to the parties, details of issue price, class of shares issued	No issuance of shares
8.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not applicable

**ALKEM LABORATORIES LTD.****Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,

Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955

• Email: contact@alkem.com • Website: www.alkemlabs.com

• CIN: L00305MH1973PLC174201

9.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	The Shareholders' Agreement has been amended pursuant to the Amendment Agreement as per the details mentioned in serial no. 2 of this table. The relevant details are as follows: (a) Name of the parties to the agreement: Please refer to serial no.1 of this table. (b) Nature of the agreement: Amendment Agreement to Amended and Restated Shareholders Agreement dated 29 th March, 2017. (c) Date of execution of the agreement: 19 th May, 2023 (d) Details of amendment and impact thereof or reasons of termination and impact thereof: The Company and the promoter shareholders of the Company have agreed to amend the Shareholders' Agreement by entering into the Amendment Agreement to include the name of DMS Trust as a member to the Shareholders' Group II and to update the list of members in Shareholders' Group I and Shareholders' Group II to reflect the changes in the constituents thereof since the date of the Shareholders Agreement. The execution of the Amendment Agreement will not result in any effective change in management and control of the Company.
----	---	---

Kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

Manish Narang

President - Legal, Company Secretary & Compliance Officer